Aptamers as Therapeutics.

Published

Journal Article (Review)

Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual disorders, thrombosis, and cancer.

Full Text

Duke Authors

Cited Authors

  • Nimjee, SM; White, RR; Becker, RC; Sullenger, BA

Published Date

  • January 6, 2017

Published In

Volume / Issue

  • 57 /

Start / End Page

  • 61 - 79

PubMed ID

  • 28061688

Pubmed Central ID

  • 28061688

Electronic International Standard Serial Number (EISSN)

  • 1545-4304

Digital Object Identifier (DOI)

  • 10.1146/annurev-pharmtox-010716-104558

Language

  • eng

Conference Location

  • United States